By means of a non-obese diabetic / severe combined immunodeficiency disease (NOD / SCID) xenotransplant assay in combination with specific cell surface markers (CD44 + CD24 - / low), CSCs were enriched from metastatic and primary breast tumors and were shown to have the ability to
reestablish tumor heterogeneity after transplantation [1].